M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with manufacturing sites in the U.S. and Japan.
India scrutinizes whistleblower case against Sun; FDA slaps warning letter on valsartan API maker; Eisai and UCL push anti-tau drug into the clinic.
India’s stock regulators say they're examining a whistleblower complaint against top domestic drugmaker Sun Pharma.
The Chinese API maker at the heart of a global scare and recall of blood pressure medicines has been savaged in an FDA warning letter.
CDMO Lonza is joining a rush of companies looking to cash in on China's eases drug regulations by building a biologics facility there.
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Of 31 drugs the Chinese government listed for a pilot bidding program, multinational pharmas landed only two contracts.
The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.
Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.
A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.